Protalix BioTherapeutics (PLX) Accounts Payables (2010 - 2026)

Protalix BioTherapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 3.98% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (up 3.98% YoY), while the FY2025 annual figure was $5.3 million, up 16.02% from the prior year.
• Accounts Payables was $4.3 million for Q1 2026 at Protalix BioTherapeutics, down from $5.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $19.6 million in Q3 2024 to a low of $4.1 million in Q2 2024.
• Historically, Accounts Payables has averaged $10.2 million across 5 years, with a median of $6.7 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables soared 126.07% in 2022, then plunged 78.09% in 2024.
• A 5-year view of Accounts Payables shows it stood at $5.9 million in 2022, then slipped by 26.31% to $4.3 million in 2023, then advanced by 4.93% to $4.5 million in 2024, then grew by 16.02% to $5.3 million in 2025, then decreased by 18.52% to $4.3 million in 2026.
• The last three Accounts Payables figures came in at $4.3 million (Q1 2026), $5.3 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.